LENZ Therapeutics, Inc.
3.40%
1,050,599
1815776
52635N103
Nov 4, 2025
Nov 10, 2025, 04:48 PM
Reporting Persons (9)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | Partnership | 3.40% | 1,050,599 | 1,050,599 | 0 |
| Versant Ventures VI GP, L.P. | Partnership | 3.40% | 1,050,599 | 0 | 1,050,599 |
| Versant Ventures VI GP-GP, LLC | Other | 3.40% | 1,050,599 | 0 | 1,050,599 |
| Versant Vantage II, L.P. | Partnership | 2.70% | 842,162 | 842,162 | 0 |
| Versant Vantage II GP, L.P. | Partnership | 2.70% | 842,162 | 0 | 842,162 |
| Versant Vantage II GP-GP, LLC | Other | 2.70% | 842,162 | 0 | 842,162 |
| Versant Venture Capital VII, L.P. | Partnership | 2.70% | 834,661 | 834,661 | 0 |
| Versant Ventures VII GP, L.P. | Partnership | 2.70% | 834,661 | 0 | 834,661 |
| Versant Ventures VII GP-GP, LLC | Other | 2.70% | 834,661 | 0 | 834,661 |
Disclosure Items (2)
Common Stock, par value $0.00001 per share
LENZ Therapeutics, Inc.
201 Lomas Santa Fe Dr., Solana Beach, CA, 92075
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
On September 30, 2025, Versant VI sold 132,944 shares of Common Stock at a price per share of $46.0143 for aggregate proceeds of approximately $6,117,326.37. On September 30, 2025, Versant VII sold 92,030 shares of Common Stock at a price per share of $46.0143 for aggregate proceeds of approximately $4,234,696.91.